company background image
2QG logo

Quantum Genomics Société Anonyme BST:2QG Stock Report

Last Price

€0.088

Market Cap

€3.6m

7D

0%

1Y

n/a

Updated

09 Mar, 2024

Data

Company Financials +

Quantum Genomics Société Anonyme

BST:2QG Stock Report

Market Cap: €3.6m

2QG Stock Overview

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases.

2QG fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Quantum Genomics Société Anonyme Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Quantum Genomics Société Anonyme
Historical stock prices
Current Share Price€0.088
52 Week High€0.17
52 Week Low€0.077
Beta0.71
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-98.16%
5 Year Change-98.22%
Change since IPO-95.15%

Recent News & Updates

Recent updates

Shareholder Returns

2QGDE BiotechsDE Market
7D0%3.3%1.6%
1Yn/a35.8%6.4%

Return vs Industry: Insufficient data to determine how 2QG performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 2QG performed against the German Market.

Price Volatility

Is 2QG's price volatile compared to industry and market?
2QG volatility
2QG Average Weekly Movementn/a
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2QG has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 2QG's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20054Jean-Philippe Milonhttps://www.quantum-genomics.com

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs.

Quantum Genomics Société Anonyme Fundamentals Summary

How do Quantum Genomics Société Anonyme's earnings and revenue compare to its market cap?
2QG fundamental statistics
Market cap€3.56m
Earnings (TTM)-€18.07m
Revenue (TTM)€19.92k

178.5x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2QG income statement (TTM)
Revenue€19.92k
Cost of Revenue€19.75m
Gross Profit-€19.73m
Other Expenses-€1.65m
Earnings-€18.07m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.52
Gross Margin-99,061.89%
Net Profit Margin-90,752.20%
Debt/Equity Ratio179.2%

How did 2QG perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.